Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)

SHA:603567 Revenue

Heilongjiang ZBD Pharmaceutical had revenue of 111.88M CNY in the quarter ending September 30, 2026, a decrease of -45.36%. This brings the company's total for the last twelve months to 286.39M, down -82.04% year-over-year. In the year 2025, Heilongjiang ZBD Pharmaceutical had annual revenue of 797.34M, down -70.51%. That makes Heilongjiang ZBD Pharmaceutical the 29,061st largest company in the world by revenue and 4,895th in China.

• Revenue (ttm): 286.39M
• Revenue Growth: -82.04%
• P/S Ratio: 15.76
• Revenue / Employee: 146.04K
• Employees: 1,961
• Market Cap: 4.42B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Industry 446.51M 58.1%
• Commercial and Medicinal Sales 321.96M 41.9%

Fiscal year ended Dec 31, 2025 See the full SHA:603567 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	797.34M	-1.91B	-70.51%
Dec 31, 2024	2.70B	-434.25M	-13.84%
Dec 31, 2023	3.14B	-1.08B	-25.53%
Dec 31, 2022	4.21B	87.33M	2.12%
Dec 31, 2021	4.13B	723.07M	21.24%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 11, 2026

Data Sources Report a data error